Related Experiment Video
Updated: Mar 24, 2026
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
Thiamine pyrophosphate suppresses platelet activation by modulating PI3K-Akt and MAPK pathways: An integrated network
Qin Li1, Ruping Yang2, Meng Wu3
1School of Pharmacy, Guizhou Medical University, Guiyang, 561113, China; Department of Pharmacology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang, 561113, China.
Aims:
Aberrant platelet activation is a major contributor to thrombotic pathologies such as atherosclerosis and acute coronary syndrome. Previous studies have suggested that supraphysiological doses of thiamine pyrophosphate (TPP), the primary active form of vitamin B1, may hold therapeutic promise for cardiovascular diseases. Here, we aimed to investigate the antithrombotic effects of TPP and elucidate its underlying mechanisms.
Materials And Methods:
The antiplatelet activity of TPP was assessed in vitro using human platelets stimulated with various agonists. Assays included aggregation, secretion, adhesion, spreading, flow cytometry, and immunoblotting. Network pharmacology and molecular docking were employed to predict targets. Complementary in vivo studies in mice evaluated effects on coagulation, tail-bleeding time, and FeCl3-induced arterial thrombosis.
Key Findings:
Network pharmacology identified 177 potential targets that link TPP to thrombosis, with significant enrichment in the phosphatidylinositol 3-kinase-adenosine diphosphate (PI3K-Akt) and mitogen-activated protein kinase (MAPK) signaling pathways. In vitro, TPP effectively inhibited human platelet activation, including aggregation, integrin αIIbβ3 activation, and P-selectin expression, without affecting the basal receptor levels or cell viability. It also suppressed adhesion, spreading, calcium mobilization, and key signaling phosphorylation events. In a murine model, TPP gavage (7-day) significantly attenuated FeCl3-induced arterial thrombosis without impairing normal hemostasis.
Significance:
Our study demonstrated that supraphysiological TPP exerts multitargeted effects by synergistically suppressing PI3K-Akt/GSK3β and p38/ERK-MAPK axes. These findings reveal a novel biological function of TPP and suggest that this endogenous nutrient could be a promising antiplatelet drug for the prevention of thrombosis, highlighting the intersection between nutrition and cardiovascular health.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
01:20The JAK-STAT Signaling Pathway
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:42Microtubule Associated Proteins (MAPs)
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...